322 related articles for article (PubMed ID: 31075279)
1. Sudden cardiac death in nonischemic cardiomyopathy.
Kadakia RS; Link MS; Dominic P; Morin DP
Prog Cardiovasc Dis; 2019; 62(3):235-241. PubMed ID: 31075279
[TBL] [Abstract][Full Text] [Related]
2. Risk of Arrhythmic Death in Patients With Nonischemic Cardiomyopathy: JACC Review Topic of the Week.
Chrispin J; Merchant FM; Lakdawala NK; Wu KC; Tomaselli GF; Navara R; Torbey E; Ambardekar AV; Kabra R; Arbustini E; Narula J; Guglin M; Albert CM; Chugh SS; Trayanova N; Cheung JW
J Am Coll Cardiol; 2023 Aug; 82(8):735-747. PubMed ID: 37587585
[TBL] [Abstract][Full Text] [Related]
3. Sudden cardiac death in nonischemic cardiomyopathy: Refining risk assessment.
Zipse MM; Tzou WS
J Cardiovasc Electrophysiol; 2017 Nov; 28(11):1361-1366. PubMed ID: 28670752
[TBL] [Abstract][Full Text] [Related]
4. Implantable cardioverter defibrillators for primary prevention in patients with nonischemic cardiomyopathy: A systematic review and meta-analysis.
Akel T; Lafferty J
Cardiovasc Ther; 2017 Jun; 35(3):. PubMed ID: 28129469
[TBL] [Abstract][Full Text] [Related]
5. Rationale and study protocol for the BRITISH randomized trial (Using cardiovascular magnetic resonance identified scar as the benchmark risk indication tool for implantable cardioverter defibrillators in patients with nonischemic cardiomyopathy and severe systolic heart failure).
Flett A; Cebula A; Nicholas Z; Adam R; Ewings S; Prasad S; Cleland JG; Eminton Z; Curzen N
Am Heart J; 2023 Dec; 266():149-158. PubMed ID: 37777041
[TBL] [Abstract][Full Text] [Related]
6. Primary prevention implantable cardioverter-defibrillator and opportunities for sudden cardiac death risk assessment in non-ischaemic cardiomyopathy.
Pathak RK; Sanders P; Deo R
Eur Heart J; 2018 Aug; 39(31):2859-2866. PubMed ID: 30020440
[TBL] [Abstract][Full Text] [Related]
7. The prognostic role of late gadolinium enhancement on cardiac magnetic resonance in patients with nonischemic cardiomyopathy and reduced ejection fraction, implanted with cardioverter defibrillators for primary prevention. A systematic review and meta-analysis.
Anagnostopoulos I; Kousta M; Kossyvakis C; Lakka E; Paraskevaidis NT; Schizas N; Alexopoulos N; Deftereos S; Giannopoulos G
J Interv Card Electrophysiol; 2022 Apr; 63(3):523-530. PubMed ID: 34218421
[TBL] [Abstract][Full Text] [Related]
8. Ventricular arrhythmias in patients with newly diagnosed nonischemic cardiomyopathy: Insights from the PROLONG study.
Duncker D; König T; Hohmann S; Bauersachs J; Veltmann C
Clin Cardiol; 2017 Aug; 40(8):586-590. PubMed ID: 28333373
[TBL] [Abstract][Full Text] [Related]
9. Sudden death mechanisms in nonischemic cardiomyopathies: Insights gleaned from clinical implantable cardioverter-defibrillator trials.
Steinberg BA; Mulpuru SK; Fang JC; Gersh BJ
Heart Rhythm; 2017 Dec; 14(12):1839-1848. PubMed ID: 28919378
[TBL] [Abstract][Full Text] [Related]
10. CMR-Based Risk Stratification of Sudden Cardiac Death and Use of Implantable Cardioverter-Defibrillator in Non-Ischemic Cardiomyopathy.
Keil L; Chevalier C; Kirchhof P; Blankenberg S; Lund G; Müllerleile K; Magnussen C
Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281168
[TBL] [Abstract][Full Text] [Related]
11. Should Primary Prevention ICDs Still Be Placed in Patients with Non-ischemic Cardiomyopathy? A Review of the Evidence.
Ganga HV; Maan A; Kevin Heist E
Curr Cardiol Rep; 2018 Mar; 20(5):31. PubMed ID: 29574588
[TBL] [Abstract][Full Text] [Related]
12. Positron emission tomography absolute stress myocardial blood flow for risk stratification in nonischemic cardiomyopathy.
Middour TG; Rosenthal TM; Abi-Samra FM; Bernard ML; Khatib S; Polin GM; Rogers PA; Bober RM; Morin DP
J Cardiovasc Electrophysiol; 2020 May; 31(5):1137-1146. PubMed ID: 32064730
[TBL] [Abstract][Full Text] [Related]
13. Myocardial fibrosis predicts appropriate device therapy in patients with implantable cardioverter-defibrillators for primary prevention of sudden cardiac death.
Iles L; Pfluger H; Lefkovits L; Butler MJ; Kistler PM; Kaye DM; Taylor AJ
J Am Coll Cardiol; 2011 Feb; 57(7):821-8. PubMed ID: 21310318
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Implantable Cardioverter-Defibrillator Therapy in Patients With Nonischemic Cardiomyopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Anantha Narayanan M; Vakil K; Reddy YN; Baskaran J; Deshmukh A; Benditt DG; Adabag S
JACC Clin Electrophysiol; 2017 Sep; 3(9):962-970. PubMed ID: 29759721
[TBL] [Abstract][Full Text] [Related]
15. Therapy optimization in patients with heart failure: the role of the wearable cardioverter-defibrillator in a real-world setting.
Röger S; Rosenkaimer SL; Hohneck A; Lang S; El-Battrawy I; Rudic B; Tülümen E; Stach K; Kuschyk J; Akin I; Borggrefe M
BMC Cardiovasc Disord; 2018 Mar; 18(1):52. PubMed ID: 29544442
[TBL] [Abstract][Full Text] [Related]
16. Relationship of LVEF and Myocardial Scar to Long-Term Mortality Risk and Mode of Death in Patients With Nonischemic Cardiomyopathy.
Klem I; Klein M; Khan M; Yang EY; Nabi F; Ivanov A; Bhatti L; Hayes B; Graviss EA; Nguyen DT; Judd RM; Kim RJ; Heitner JF; Shah DJ
Circulation; 2021 Apr; 143(14):1343-1358. PubMed ID: 33478245
[TBL] [Abstract][Full Text] [Related]
17. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy?
Ellenbogen KA; Levine JH; Berger RD; Daubert JP; Winters SL; Greenstein E; Shalaby A; Schaechter A; Subacius H; Kadish A;
Circulation; 2006 Feb; 113(6):776-82. PubMed ID: 16461817
[TBL] [Abstract][Full Text] [Related]
18. Implantable Cardioverter Defibrillators for Primary Prevention of Mortality in Patients With Nonischemic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials.
Stavrakis S; Asad Z; Reynolds D
J Cardiovasc Electrophysiol; 2017 Jun; 28(6):659-665. PubMed ID: 28316104
[TBL] [Abstract][Full Text] [Related]
19. Sudden Cardiac Death Substrate Imaged by Magnetic Resonance Imaging: From Investigational Tool to Clinical Applications.
Wu KC
Circ Cardiovasc Imaging; 2017 Jul; 10(7):. PubMed ID: 28637807
[TBL] [Abstract][Full Text] [Related]
20. Current Indications for Implantable Cardioverter Defibrillators in Non-Ischemic Cardiomyopathies and Channelopathies.
González-Torrecilla E; Arenal A; Atienza F; Datino T; Bravo L; Ruiz P; Ávila P; Fernández-Avilés F
Rev Recent Clin Trials; 2015; 10(2):111-27. PubMed ID: 25845953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
